Loading
Life sciences · Journal article
Frontiers in Endocrinology · October 22, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Thyroid hormones are involved in multiple metabolic pathways in the body and are essential for maintaining organ functions across the lifespan. Aging-related thyroid dysfunction has a bidirectional relationship with the development of chronic diseases including metabolic syndrome, diabetes, and cardiovascular disease, and contributes to the progression of cardiovascular-kidney-metabolic (CKM) syndrome via complex pathophysiological mechanisms. Systematically elaborating on the characteristics of thyroid function related to aging and its regulatory role in metabolism and cardiovascular homeostasis, can provide new therapeutic strategies and theoretical basis for revealing the molecular network and metabolic process of the CKM syndrome. In this review, we have summarized the manifestations of thyroid hormone homeostasis in age-related changes, and the underlying potential mechanisms during aging and longevity processes. Moreover, we systematically elucidated the pivotal role of thyroid hormones in cardiovascular and renal homeostasis, discussed the interplay between thyroid dysfunction and metabolic risk factors in CKM syndrome, particularly issues related to obesity, type 2 diabetes, and dyslipidemia. Patients with thyroid dysfunction develop CKM syndrome through a positive feedback loop centered on metabolic disorders and organic dysfunction. Moreover, we pointed out that novel drugs targeting thyroid hormone receptors are expected to slow down the progression of CKM syndrome and reduce cardiovascular risks.